Stoky
Back to explore
N
NoahListening
A
AshListening
0:00 / 0:00I. Biotechnology Pipeline and Business Overview
IBRX logo

ImmunityBio Revenue Surges 700% to $113 Million Following FDA Approval of ANKTIVA

IBRX10-KFiling Date: 2/23/2026
ImmunityBio, Inc.
Description

What this story covers

ImmunityBio transitioned to a commercial-stage biotech in 2025, with ANKTIVA sales driving a 700% revenue increase. Despite this growth, the company faces a $351.5 million net loss, high debt levels, and ongoing legal arbitrations over milestone payments.

Story snapshot

CompanyImmunityBio, Inc.
TickerIBRX
VariantStandard detailed
Duration11:32
Filing type10-K
PeriodAnnual 2025
IndustryHealthcare & Pharmaceuticals
Accession0001326110-26-000030
Sources1

Full Story Script

Content not available for this story.

Primary Sources

sec_filing10-KView on SEC.gov →

Ask Noah

Question the story, source filings, and key financial signals.

Sign in to chat with Noah

Ask questions about revenue, margins, risk factors, filings and more. Noah uses retrieval-augmented analysis over raw financial disclosures.

Sign in